Testing a new radiotherapy approach for non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and feasibility of a novel radiotherapy technique called primer shot fractionation for patients with non-small cell lung cancer (NSCLC). The approach involves administering an initial radiotherapy fraction followed by a treatment break to enhance tumor radiosensitivity through reoxygenation. The trial is designed as a prospective non-randomized feasibility study, utilizing a 3+3 phase design to assess increasing treatment breaks and includes an expansion cohort for further evaluation. Patients with stage 2-4 NSCLC who are referred for palliative radiotherapy will be included in the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* NSCLC (either pathology proven or sufficient clinical suspicion to be treated as NSCLC), referred for palliative radiotherapy of at least the primary tumor site.
* Stage 2-4
* WHO performance score 0-2.
* Provision of signed, written and dated IC prior to any study specific procedures.

Exclusion Criteria:

* Interstitial lung disease
* Treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors
* Prior thoracic radiotherapy (\>20 Gy EQD2 a/b 3) overlapping with the current planning target volume

Where it's running

• Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
  Amsterdam, Netherlands Recruiting

Study contacts

• Study coordinator: Zeno Gouw
• Email: z.gouw@nki.nl
• Phone: +31205129111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Therapeutic cancer vaccine for patients with advanced lung cancer resistant to immunotherapy

  This study is testing a new cancer vaccine called OSE2101 to see if it can help people with advanced lung cancer who haven't responded to other immunotherapy treatments.

  Recruiting at 153 sites Phase 3 OSE Immunotherapeutics · Beverly Hills, California and 206 other locations · NCT06472245

• Omitting re-excision after complete primary melanoma excision

  This trial tests whether people with pT1b–pT4b cutaneous melanoma whose tumors were completely removed can safely skip the usual re-excision surgery.

  Recruiting at 10 sites Phase 3 The Netherlands Cancer Institute · 's-Hertogenbosch and 20 other locations · NCT07530887

• Living long-term with advanced GIST on tyrosine kinase inhibitors

  This observational project will collect medical records and patient questionnaires to see how long-term tyrosine kinase inhibitor treatment affects quality of life and survivorship for adults with advanced or metastatic GIST who have taken TKIs for at least two years.

  Recruiting The Netherlands Cancer Institute · Amsterdam, North Holland · NCT07522762

• Ga68-PSMA PET/CT to tell radiation damage from tumor growth in brain metastases

  This project will test whether a Ga68-PSMA PET/CT scan can tell radiation necrosis apart from tumor regrowth in adults with brain metastases from lung cancer, melanoma, or breast cancer.

  Recruiting The Netherlands Cancer Institute · Amsterdam · NCT07511933

• Combining olaparib with cisplatin HIPEC during interval cytoreductive surgery for ovarian cancer

  This study will test whether giving the PARP inhibitor olaparib around interval cytoreductive surgery with heated intraperitoneal cisplatin (HIPEC) is safe and feasible for adults with advanced high‑grade serous ovarian or fallopian tube cancer who responded to neoadjuvant chemotherapy.

  Recruiting Phase 1/2 The Netherlands Cancer Institute · Amsterdam · NCT07460180

• Whole-body HER2 PET/CT to see how 89Zr-trastuzumab accumulates in HER2-positive or HER2-mutated advanced NSCLC

  This study tests whether 89Zr-trastuzumab PET/CT can show how much tracer builds up in tumors of adults with HER2-positive or HER2-mutated advanced NSCLC.

  Recruiting Phase 1 The Netherlands Cancer Institute · Amsterdam, North Holland · NCT07436858

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.